A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended (CLIMAX)

AstraZeneca

Status: Completed

Conditions: Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT00922090

NIS-NKR-SER-2009/1

Details and patient eligibility

About

The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.

Enrollment: 1,494 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as Schizophrenia according to DSM-IV-TR criteria
• Patients who are taking Seroquel XR no longer than 1 month
• Patients who get antipsychotics monotherapy at least 1 week before enroll in this study

Exclusion criteria

• First episode, drug naive schizophrenic subjects.
• Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis,concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.
• Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment.